var data={"title":"Trametinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Trametinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/578150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=trametinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Trametinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510602\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mekinist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963806\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mekinist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20498993\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, MEK Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510628\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Confirm BRAF V600 mutation status prior to treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (metastatic or unresectable) (with BRAF V600E or BRAF V600K mutations):</b> Oral: 2 mg once daily (either as a single-agent or in combination with dabrafenib), continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic) (with BRAF V600E mutation): </b>Oral: 2 mg once daily (in combination with dabrafenib); continue until disease progression or unacceptable toxicity (Planchard 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Missed doses:</i> Do not take a missed dose within 12 hours of the next dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510625\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Mild to moderate impairment (GFR &ge;30 mL/minute/1.73 m<sup>2</sup>): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Severe impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, renal excretion is low and is unlikely to affect drug exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510626\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Mild impairment (total bilirubin &le; ULN and AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN with any AST): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510624\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recommended trametinib dose reductions for toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First dose reduction: 1.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose reduction: 1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subsequent modification (if unable to tolerate 1 mg once daily): Permanently discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If using combination therapy, refer to dabrafenib monograph for recommended dabrafenib dose reductions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asymptomatic, 10% or greater absolute decrease in LVEF from baseline and LVEF is below institutional lower limits of normal (LLN) from pretreatment value: Interrupt trametinib therapy for up to 4 weeks. If LVEF improves to normal within 4 weeks following therapy interruption, resume at a lower dose level. If LVEF does not improve to normal within 4 weeks following therapy interruption, permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;20% absolute decrease in LVEF from baseline and LVEF is below institutional LLN: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptomatic heart failure: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatologic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intolerable Grade 2 skin toxicity or Grade 3 or 4 skin toxicity: Interrupt trametinib therapy for up to 3 weeks. If toxicity improves within 3 weeks, resume at a lower dose level. If toxicity does not improve within 3 weeks following therapy interruption, permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New primary cutaneous malignancies: No trametinib dosage modification is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fever:</b> Fever &gt;40&deg;C (104&deg;F) or fever (any severity) complicated by rigors, hypotension, dehydration, or renal failure: Interrupt trametinib therapy until fever resolves, then resume at the same or a lower dose level. May require prophylactic antipyretics (secondary prophylaxis) upon resumption. Administer corticosteroids (eg, prednisone 10 mg daily or equivalent) for at least 5 days for second or subsequent pyrexia if temperature does not return to baseline within 3 days of onset of fever, or for fever associated with complications (eg, dehydration, hypotension, severe chills/rigors with no evidence of active infection).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemorrhage:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 hemorrhage:  Interrupt trametinib therapy. If hemorrhage improves, resume at a lower dose level. If hemorrhage does not improve following therapy interruption, permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 hemorrhage: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ocular:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uveitis and iritis: No trametinib dosage modification necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Retinal pigment epithelial detachments (RPED): Interrupt trametinib therapy for up to 3 weeks. If improves within 3 weeks following therapy interruption, resume at the same or lower dose level. If RPED does not improve within 3 weeks following therapy interruption, reduce dose or permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Retinal vein occlusion: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary:</b> Interstitial lung disease or pneumonitis: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uncomplicated DVT or PE: Interrupt trametinib therapy for up to 3 weeks. If improves to &le; grade 1 within 3 weeks following therapy interruption, resume at a lower dose level. If toxicity does not improve within 3 weeks following therapy interruption, permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Life-threatening PE: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intolerable Grade 2 adverse reaction or any Grade 3 adverse reaction: Interrupt therapy. If toxicity improves to &le; grade 1 following therapy interruption, resume at a lower dose level. If toxicity does not improve following therapy interruption, permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 adverse reaction:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First occurrence: Interrupt trametinib therapy until improves to &le;grade 1, then resume at a lower dose level <b>or</b> permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recurrence: Permanently discontinue trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New primary noncutaneous malignancy: No trametinib dosage modification is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617039\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mekinist: 0.5 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510603\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49639341\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204114s004lbl.pdf#page=32&amp;token=fDtqNcwBjpnu67ZmmfCR4pPNB5jjpheq3iPyV4R1dYiuPjvVqc3eiKURAE6RdXFFKT+v/qAMTKcV6C2Duq8zibLK8BlMUVdkYRSgF1X6rOIqd7EdDpa+MewS/NGccFVQ&amp;TOPIC_ID=89685\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204114s004lbl.pdf#page=32</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510630\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer at least 1 hour before or 2 hours after a meal. Administer dose at the same time each day, whether administered as a single agent or in combination with dabrafenib (when administered in combination with dabrafenib, take the once daily trametinib dose either with the morning or with the evening dabrafenib dose).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104599\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20498995\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (metastatic or unresectable): </b>Treatment of unresectable or metastatic melanoma in patients with a BRAF V600E or BRAF V600K mutation (as detected by an approved test), either as a single-agent or in combination with dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Trametinib is not indicated for use in melanoma patients who have received prior BRAF-inhibitor therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic): </b>Treatment of metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E mutation as detected by an approved test (in combination with dabrafenib).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510600\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trametinib may be confused with cobimetinib, dabrafenib, vemurafenib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20856360\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adverse reactions reported with monotherapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (15%), cardiomyopathy (7% to 11%; defined as cardiac failure, decreased left ventricular ejection fraction, or left ventricular dysfunction)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin toxicity (87%, most commonly dermatitis acneiform rash, palmar-plantar erythrodysesthesia, erythema, skin rash; severe: 12%; severe toxicity and secondary skin infection requiring hospitalization: 6%), skin rash (57%), acneiform eruption (19%), xeroderma (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoalbuminemia (42%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (43%), stomatitis (15%), abdominal pain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (38%), lymphedema (32%; includes edema, peripheral edema), hemorrhage (13%; includes epistaxis, gingival bleeding, hematochezia, rectal hemorrhage, melena, vaginal hemorrhage, hemorrhoidal hemorrhage, hematuria, conjunctival hemorrhage; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (60%), increased serum ALT (39%), increased serum alkaline phosphatase (24%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased left ventricular ejection fraction (5%, &ge;20% below baseline), bradycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Paronychia (10%), pruritus (10%), cellulitis, folliculitis, pustular rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Rhabdomyolysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, dry eye syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Interstitial pulmonary disease (&le;2%), pneumonitis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Retinal detachment, retinal vein occlusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adverse reactions reported with dual therapy (trametinib plus dabrafenib):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (25% to 26%), peripheral edema (21% to 25%; includes edema and lymphedema; grades 3/4: &le;1% ), prolonged Q-T Interval on ECG (4% QTcF increased &gt;60 msec; &lt;1% QTcF prolongation to &gt;500 msec)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (51%), headache (30% to 33%), chills (23% to 31%), dizziness (11% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin toxicity (55% any skin toxicity; severe toxicity: &lt;1%), skin rash (28% to 42%; includes generalized rash, pruritic rash, erythematous rash, papular rash, vesicular rash, macular rash, maculopapular rash, folliculitis rash), xeroderma (10% to 31%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (60% to 71%), hyponatremia (24% to 57%), hypoalbuminemia (48% to 53%), hypophosphatemia (36% to 38%), exacerbation of diabetes mellitus (27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (34% to 45%), vomiting (25% to 33%), diarrhea (30% to 32%), decreased appetite (29%), abdominal pain (18% to 26%), constipation (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (44% to 50%; grades 3/4: 6% to 8%), leukopenia (48%; grades 3/4: 8%), anemia (43% to 46%; grades 3/4: 2% to 10%), lymphocytopenia (32% to 42%; grades 3/4: 8% to 14%), hemorrhage (18% to 23%; includes epistaxis, hematochezia, decreased hemoglobin, purpura, rectal hemorrhage; grades 3/4: 2%; includes hepatic hematoma, duodenal ulcer hemorrhage), thrombocytopenia (19% to 21%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (49% to 64%), increased serum AST (59% to 61%), increased serum ALT (32% to 48%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (25% to 26%), myalgia (13% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (20% to 22%), dyspnea (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (54% to 57%), febrile reaction (complicated with dehydration: 2%, complicated with severe chills/rigors: &lt;1%, complicated with renal failure: &lt;1%, complicated with syncope: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (&lt;10%), cardiomyopathy (6%), venous thromboembolism (3%; deep vein thrombosis, pulmonary embolism), hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Intracranial hemorrhage (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (6%), pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Basal cell carcinoma (3%), squamous cell carcinoma of skin (3%; including keratoacanthoma)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Rhabdomyolysis (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Malignant melanoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20498996\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to trametinib or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510608\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia (including grade 3 and 4 events) has been observed when used in combination with dabrafenib. Monitor complete blood counts at baseline and as clinically needed during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac events: Cardiac events such as heart failure, left ventricular dysfunction, or decreased left ventricular ejection fraction (LVEF) were observed in clinical trials (for single-agent trametinib and when used in combination with dabrafenib). The median time to onset of cardiomyopathy in melanoma patients for single-agent trametinib was ~2 months (range: 16 to 156 days) and ~8 months (range: ~1 to 25 months) when used in combination with dabrafenib. The median time of onset of cardiomyopathy in patients with NSCLC was 6.7 months (range: 1.4 to 14.1 months). In some patients, cardiomyopathy developed within the first month of treatment. Assess LVEF (by echocardiogram or MUGA scan) prior to therapy initiation, at one month, and then at 2- to 3-month intervals while on therapy. Cardiac dysfunction may require treatment interruption, dosage reduction, or discontinuation; such measures resulted in resolution of cardiomyopathy in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Dermatologic toxicity (eg, rash, dermatitis, acneiform rash, palmar-plantar erythrodysesthesia syndrome, and erythema) was commonly observed in trametinib-treated patients (either as a single-agent or when used in combination with dabrafenib); some patients required hospitalization for severe toxicity or for secondary skin infections. In melanoma studies, the median time to onset and resolution of skin toxicity for single-agent trametinib was 15 days (range: 1 to 221 days) and 48 days (range: 1 to 282 days), respectively. The median time to onset and resolution of skin toxicity for combination therapy was 2 months (range: 1 day to 22 months) and 1.2 months (range: 1 day to ~24 months), respectively in melanoma studies. Monitor for dermatologic toxicity and signs/symptoms of secondary infections. Treatment interruption, dose reduction, and/or therapy discontinuation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Febrile reactions: Serious febrile reactions and fever (any severity) accompanied by hypotension, rigors/chills, dehydration, or renal failure may occur when trametinib is used in combination with dabrafenib. The incidence and severity were higher with combination therapy than with single-agent dabrafenib; the median time to onset of fever was 1.2 months (range: 1 to 23 days) and duration was 3 days (range: 1 day to 1.7 months) for patients receiving combination therapy for the treatment of melanoma. Withhold trametinib for fever &gt;104&deg;F (if using in combination, withhold dabrafenib for fever &ge;101.3&deg;F) or for any fever with rigors/chills, hypotension, dehydration, or renal failure (evaluate for infection); may require prophylactic antipyretics as secondary prophylaxis upon therapy resumption. Administer corticosteroids (eg, prednisone 10 mg daily or equivalent) for at least 5 days for second or subsequent episodes of pyrexia if temperature does not return to baseline within 3 days of fever onset, or for pyrexia associated with complications (eg, dehydration, hypotension, severe chills/rigors with no evidence of active infection).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events: Colitis and GI perforation, including fatal cases, have been reported with monotherapy and when administered concomitantly with dabrafenib; monitor closely for development of colitis and GI perforations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Hemorrhage, including symptomatic bleeding in a critical area/organ, may occur with trametinib, either as a single agent or in combination with dabrafenib. Major bleeding events (some fatal) included intracranial or gastrointestinal hemorrhage. May require treatment interruption and dosage reduction; permanently discontinue trametinib (and dabrafenib) for all grade 4 hemorrhagic events and any grade 3 event that does not improve with therapy interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Elevated liver function tests have been reported with trametinib, including grade 3 and 4 events. Monitor hepatic function as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: While not reported with single-agent trametinib, hyperglycemia may occur while on combination therapy with dabrafenib; may require initiation of insulin or oral hypoglycemic agent therapy (or an increased dose if already taking). Monitor serum glucose at baseline and as clinically necessary in patients with preexisting diabetes or hyperglycemia. Instruct patients to report symptoms of severe hyperglycemia (eg, polydipsia, polyuria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: May cause hypertension; monitor blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: New primary cutaneous malignancies (which are associated with dabrafenib as single-agent therapy) may occur when trametinib is given in combination with dabrafenib. The incidence of basal cell carcinoma (BCC) in melanoma patients is ~3% for combination therapy versus 6% for single-agent dabrafenib. The median time to BCC diagnosis ranged from ~3 to 24 months for patients receiving combination therapy for the treatment of melanoma. Cutaneous squamous cell carcinomas (cuSCC), including keratoacanthoma, occurred at a lower rate for combination therapy in melanoma patients compared to single-agent dabrafenib (3% vs 10%, respectively), with a median time to diagnosis ranging from ~2 to 17 months for combination therapy. Cases of cuSCC also occurred in patients with NSCLC, with a first occurrence onset ranging from 25 days to ~12 months. New primary melanoma occurred rarely in patients receiving trametinib. Dermatologic exams should be performed prior to initiation of combination therapy, every 2 months while receiving combination treatment, and for up to 6 months following discontinuation. There are case reports of noncutaneous malignancies, including pancreatic cancer (KRAS mutation-positive), colorectal cancer (recurrent NRAS mutation-positive), hand and neck cancer, and glioblastoma, with combination therapy; monitor for signs/symptoms of noncutaneous malignancies. No trametinib dosage modification is necessary for new primary cutaneous and noncutaneous malignancies; dabrafenib should be permanently discontinued if RAS mutation-positive noncutaneous malignancies develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Retinal pigment epithelial detachments (RPED) and retinal vein occlusion were seen in clinical trials (rare). Detachments were typically bilateral and multifocal and occurred in the central macular area of the retina. Retinal vein occlusion may lead to macular edema, decreased visual function, neovascularization, and glaucoma. Promptly (within 24 hours) refer patients for ophthalmological evaluations if loss of vision or other visual disturbances occur. Ophthalmic exams (including retinal evaluation) should be performed periodically during treatment and with visual disturbances. Interrupt trametinib therapy for RPED; may resume if resolves within 3 weeks; reduce the dose or discontinue if not resolved within 3 weeks. Permanently discontinue if retinal vein occlusion develops. Uveitis and iritis have been reported when trametinib is used in combination with dabrafenib and are managed symptomatically with ophthalmic steroid and mydriatic drops (does not require alteration in trametinib therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Interstitial lung disease (ILD) and pneumonitis were observed in clinical trials. The median time to initial presentation in melanoma patients was ~5 months (range: 2 to ~6 months). Monitor for new or progressive pulmonary symptoms (eg, cough, dyspnea, hypoxia, pleural effusion, infiltrates); withhold treatment if symptoms occur; permanently discontinue with diagnosis of ILD or pneumonitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Venous thromboembolism: Venous thromboembolic events (some fatal) may occur (was observed when used in combination with dabrafenib). DVT and PE occurred at an increased incidence with combination therapy. Patients should seek immediate medical attention with symptoms of DVT or PE (shortness of breath, chest pain, arm/leg swelling). Withhold trametinib for uncomplicated DVT or PE; may resume at a lower dose if improves within 3 weeks; permanently discontinue trametinib for life-threatening PE.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination therapy with dabrafenib: Serious adverse reactions (tumor promotion, hemolytic anemia), which occur with single-agent dabrafenib, may also occur when trametinib is administered in combination with dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Trametinib is not indicated for treatment of patients with melanoma who have progressed on prior BRAF-inhibitor therapy. Prior to initiating therapy, confirm BRAF mutation status with an approved test; approved for use in melanoma patients with BRAF V600K and BRAF V600E mutations and NSCLC patients with BRAF V600E mutation. Data regarding use in melanoma patients with BRAF V600K mutation is limited; compared to BRAF V600E mutation, lower response rates have been observed with BRAF V600K mutation. Data regarding other less common BRAF V600 mutations in melanoma is lacking.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616444\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616442\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89685&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Trametinib may enhance the adverse/toxic effect of Dabrafenib. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20519443\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Administration with a high-fat, high-calorie meal decreased AUC by 24%, C<sub>max</sub> by 70%, and delayed T<sub>max</sub> by ~4 hours. Management: Administer 1 hour before or 2 hours after a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510605\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. Based on its mechanism of action, trametinib would be expected to cause fetal harm if administered to a pregnant woman. Females of reproductive potential should use a highly effective contraceptive during therapy and for 4 months after treatment is complete. When trametinib is used in combination with dabrafenib, a highly effective nonhormonal contraceptive method should be used (dabrafenib may diminish efficacy of hormonal contraceptives). Fertility may also be impaired in females. Due to a risk for impaired spermatogenesis, males who may want to father a child should seek fertility/family planning counseling prior to initiating combination therapy with dabrafenib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510607\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if trametinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 4 months after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510632\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">BRAF V600K or V600E mutation status (prior to treatment); CBC and liver function tests at baseline and periodically; assess LVEF (by echocardiogram or MUGA scan) at baseline, 1 month after therapy initiation, and then at 2- to 3-month intervals; ophthalmological evaluation periodically during treatment and with visual disturbances; monitor for signs/symptoms of pulmonary toxicity (eg, cough dyspnea, hypoxia, pleural effusion, or infiltrates); monitor for dermatologic toxicity and secondary skin infections; blood pressure; diarrhea; signs/symptoms of bleeding, colitis, and GI perforations.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients receiving combination therapy with dabrafenib: Blood glucose (baseline and periodically in patients with preexisting diabetes or hyperglycemia); dermatologic exams should be performed prior to treatment initiation, every 2 months while receiving combination treatment, and for up to 6 months following therapy discontinuation. Monitor for signs/symptoms of cutaneous and noncutaneous malignancies and uveitis/iritis.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510612\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Trametinib reversibly and selectively inhibits mitogen-activated extracellular kinase (MEK) 1 and 2 activation and kinase activity. MEK is a downstream effector of the protein kinase B-raf (BRAF); BRAF V600 mutations result in constitutive activation of the BRAF pathway (including MEK1 and MEK2). Through inhibition of MEK 1 and 2 kinase activity, trametinib causes decreased cellular proliferation, cell cycle arrest, and increased apoptosis (Kim 2013). The combination of trametinib and dabrafenib allows for greater inhibition of the MAPK pathway, resulting in BRAF V600 melanoma cell death (Flaherty 2012). Trametinib plus dabrafenib has been reported to synergistically inhibit cell growth in lung cancer cell lines which are BRAF V600E-mutant (Planchard 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20510614\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; decreased with a high-fat, high-calorie meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 214 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Predominantly deacetylation (via hydrolytic enzymes) alone or with mono-oxygenation or in combination with glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 72%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 4 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1.5 hours; delayed with a high-fat, high-calorie meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (&gt;80%); urine (&lt;20% with &lt;0.1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22686898\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mekinist Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $3,623.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (30): $12,938.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24672895\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mekinist (AT, AU, BM, CZ, DK, FR, HK, HR, HU, IE, IL, IS, JP, KR, LT, MT, NL, NO, PL, PT, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Falchook GS, Lewis KD, Infante JR, et al, &ldquo;Activity of the Oral MEK Inhibitor Trametinib in Patients With Advanced Melanoma: A Phase 1 Dose-Escalation Trial,&rdquo; <i>Lancet Oncol</i>, 2012, 13(8):782-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/22805292/pubmed\" target=\"_blank\" id=\"22805292\">22805292</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty KT, Infante JR, Daud A, et al, &ldquo;Combined BRAF and MEK Inhibition in Melanoma With BRAF V600 Mutations,&rdquo; <i>N Engl J Med</i>, 2012, 367(18):1694-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/23020132/pubmed\" target=\"_blank\" id=\"23020132\">23020132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty KT, Robert C, Hersey P, et al, &ldquo;Improved Survival With MEK Inhibition in BRAF-Mutated Melanoma,&rdquo; <i>N Engl J Med</i>, 2012, 367(2):107-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/22663011/pubmed\" target=\"_blank\" id=\"22663011\">22663011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infante JR, Fecher LA, Falchook GS, et al, &ldquo;Safety, Pharmacokinetic, Pharmacodynamics, and Efficacy Data for the Oral MEK Inhibitor Trametinib: A Phase 1 Dose-Escalation Trial,&rdquo; <i>Lancet Oncol</i>, 2012, 13(8):773-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/22805291/pubmed\" target=\"_blank\" id=\"22805291\">22805291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infante JR, Papadopoulos KP, Bendell JC, et al, &ldquo;A Phase 1b Study of Trametinib, an Oral Mitogen-Activated Protein Kinase (MEK) Inhibitor, in Combination With Gemcitabine in Advanced Solid Tumours,&rdquo; <i>Eur J Cancer</i>, 2013;49(9):2077-2085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/23583440/pubmed\" target=\"_blank\" id=\"23583440\">23583440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. <i>J Clin Oncol</i>. 2014;32(33):3697-3704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/25287827/pubmed\" target=\"_blank\" id=\"25287827\">25287827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim KB, Kefford R, Pavlick AC, et al, &ldquo;Phase II study of the MED1/MEK2 Inhibitor Trametinib In Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With Or Without A BRAF Inhibitor,&rdquo; <i>J Clin Oncol</i>, 2013, 31(4):482-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/23248257/pubmed\" target=\"_blank\" id=\"23248257\">23248257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.<i> Lancet.</i> 2015;386(9992):444-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/26037941/pubmed\" target=\"_blank\" id=\"26037941\">26037941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>N Engl J Med</i>. 2014;371(20):1877-1888.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/25265492/pubmed\" target=\"_blank\" id=\"25265492\">25265492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mekinist (trametinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mekinist (trametinib) [product monograph]. Dorval, Quebec: Novartis Pharmaceuticals Canada Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27283860\"></a>Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncol</i>. 2016;17(7):984-993.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/27283860/pubmed\" target=\"_blank\" id=\"27283860\">27283860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>N Engl J Med</i>. 2015;372(1):30-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trametinib-drug-information/abstract-text/25399551/pubmed\" target=\"_blank\" id=\"25399551\">25399551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taflinar (dabrafenib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89685 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20510602\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21963806\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F20498993\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20510628\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20510625\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20510626\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20510624\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20617039\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20510603\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49639341\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20510630\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104599\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20498995\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20510600\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20856360\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20498996\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20510608\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20616444\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20616442\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F20519443\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20510605\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20510607\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20510632\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20510612\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20510614\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F22686898\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24672895\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/89685|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=trametinib-patient-drug-information\" class=\"drug drug_patient\">Trametinib: Patient drug information</a></li></ul></div></div>","javascript":null}